New Analysis Highlights Potential Of SEROQUEL For Long-term Treatment Of Bipolar Disorder
Results from a new analysis of two major clinical trials have shown that patients with bipolar disorder who received long-term treatment with SEROQUEL (quetiapine fumarate) plus a mood stabiliser were significantly less likely to have a mood event (manic, mixed or depressed) than patients on a mood stabiliser alone.
Study Suggests Risperidone Long Acting Injection Combined With Standard Treatment Helped Delay Time To Relapse In Patients With Bipolar Disorder
Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.
New Analysis Demonstrates Efficacy Of Seroquel Quetiapine Fumarate Maintenance Treatment For Bipolar I Disorder
Results from a combined analysis of two long term phase III clinical trials2, 3 have shown that patients with bipolar I disorder who received treatment with quetiapine plus a mood stabiliser showed a 70% reduction in the risk of recurrence of a mood event (manic, mixed or depressed) compared to patients on a mood stabiliser alone (HR=0.
Scientists Discover Chemical Signature Of Manic Depression
People with manic depression have a distinct chemical signature in their brains, according to a new study. The research, published in the journal Molecular Psychiatry, may also indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to cause.
Study Suggests Risperidone Long-Acting Injection Combined With Standard Treatment Helped Delay Time To Relapse In Patients With Bipolar Disorder
Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.
ACADIA Announces Presentation Of Data On Pimavanserin Co-Therapy At The 14th Biennial Winter Workshop On On Schizophrenia And Bipolar Disorders
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Murray Rosenthal, D.
Astrazeneca Submits Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression, And Seroquel R For The Treatment Of Bipolar Depression
AstraZeneca announced that the company has submitted applications in the European Union (EU) under the Mutual Recognition Procedure (MRP) for once-daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, seeking approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.
Alexza Initiates First Phase 3 Clinical Trial For AZ-004 Staccato R Loxapine
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has initiated its first Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.
Bipolar Depression Licence Application For Seroquel R
AstraZeneca has submitted an application to the Medicines and Healthcare products Regulatory Agency (MHRA) for a new licence for Seroquel(R) (quetiapine fumarate) in the UK for major depressive episodes in the framework of bipolar disorder. Quetiapine is currently licensed in the UK for the treatment of schizophrenia and manic episodes associated with bipolar disorder.
Indiana U Study May Alter Approach To Psychiatric Treatment
Indiana University School of Medicine researchers have isolated biomarkers in the blood that identify mood disorders, a breakthrough that may change the way bipolar illness is diagnosed and treated. The report will be published in the February 26 advance online edition of the journal Molecular Psychiatry.